Fludrocortisone for POTS: The Blood-Volume Drug That Makes Salt and Water Stick

The POTS drug that never touches the heart or the vessels

Line up the medications used for POTS and you can sort almost all of them by where they act. Beta blockers and ivabradine work on the heart to slow it down. Midodrine works on the blood vessels to tighten them. Fludrocortisone is the odd one out, and understanding why is the key to using it well. Fludrocortisone acts on neither the heart nor the vessels. It acts on the kidneys, and it changes how much blood is in your body in the first place.

That matters because many people with POTS are running on a genuinely small tank. A well-documented subset have reduced plasma volume, meaning there is simply less blood in circulation than there should be. When you stand, gravity pulls a chunk of that limited volume down into your legs and abdomen, even less returns to the heart, and the heart races to keep circulation going. Beta blockers turn down the racing. Midodrine narrows the pipes so less pools. Fludrocortisone does something more upstream: it makes the tank bigger.

This is educational field notes, not medical advice, and nothing here is a reason to start, stop, or change a prescription on your own. Fludrocortisone is prescription-only, its dose and monitoring are individual, and every decision belongs with your clinician. With that said, understanding the mechanism makes your own tracking far more useful, so let’s walk through how fludrocortisone works, why salt intake is written into the prescription, the potassium rule that comes with it, and exactly what to watch once it is in the picture.

How does fludrocortisone work?

Your body already has a hormone whose whole job is to manage blood volume: aldosterone, made by the adrenal glands. Aldosterone is a mineralocorticoid, and it acts on the last stretch of the kidney’s filtering tubules, telling them to pull sodium back out of the urine-to-be and return it to the blood. Water follows sodium by osmosis, so retaining salt means retaining water, and retaining water means a larger plasma volume.

Fludrocortisone (you may see the brand name Florinef) is a synthetic mineralocorticoid. It is essentially a potent, long-acting stand-in for aldosterone. Swallowed as a small daily dose, it switches on the same sodium-retaining machinery in the kidney, so more of the sodium you take in stays in your body instead of leaving in urine, and your plasma volume expands over several days.

For the low-volume, pooling POTS body, that expansion is the point. A bigger blood volume means more blood is available to return to the heart when you stand, standing circulation holds up better, and because the reflex tachycardia of POTS is largely a reaction to too little blood coming back, filling the tank often shrinks the lying-to-standing heart-rate jump. All of that happens without the drug ever acting on the heart itself.

Why salt intake is part of the prescription

Here is the fact that catches people off guard. Fludrocortisone does not create sodium. It only stops your kidneys from throwing away the sodium you already have. If you are eating a low-salt diet, there is very little sodium for it to hold on to, and the drug has almost nothing to work with. The medication and a deliberately higher salt and fluid intake are a pair, and neither does much alone in this setting.

That is why clinicians who prescribe fludrocortisone for POTS almost always pair it with a higher-salt diet and generous fluids. The salt provides the raw material; the drug keeps it in; the water expands the volume. If you have read the science of salt and fluids for POTS, fludrocortisone is best thought of as the amplifier for that same strategy, not a replacement for it. Going low-salt while on fludrocortisone quietly cancels the treatment, and it is a genuinely common reason the drug seems not to work.

How is fludrocortisone different from midodrine or a beta blocker?

All three are used in POTS, and the easiest way to keep them straight is by what part of the problem each one addresses. Fludrocortisone fills the tank. Midodrine narrows the pipes. Beta blockers and ivabradine turn down the pump.

If you are weighing the other two directions, the companion pieces on midodrine for POTS and beta blockers and HRV cover those mechanisms, ivabradine for POTS covers the pacemaker route, and the broader POTS treatment overview puts medication in context with the non-drug basics.

Does fludrocortisone actually help POTS?

Fludrocortisone has a long track record in orthostatic intolerance and is a recognized option for POTS, though its use here is off-label. The 2015 Heart Rhythm Society expert consensus statement on POTS lists it among the pharmacologic options, particularly for patients whose problem is low blood volume that has not responded to salt and fluids alone. In practice it is often reached for when the volume-expansion strategy is working directionally but needs more force than diet can provide.

Two honest caveats keep this in proportion. First, fludrocortisone treats the volume side of POTS, not its cause. It does not repair the autonomic disturbance, reverse deconditioning, or fix the pooling directly. It makes upright life more tolerable by keeping the tank fuller while the structural work happens. Second, it does not suit everyone. Someone whose blood pressure already runs high, or who retains fluid easily, may get little benefit and could feel worse, which is why matching the drug to the POTS subtype matters. The person it helps most is often the one whose readings point toward low blood volume rather than a hyperadrenergic surge.

The potassium rule, and the other things that get watched

The kidney’s sodium-retaining machinery does not work for free. To pull sodium back into the blood, it pushes potassium the other way, into the urine. Magnesium goes with it to a lesser degree. So the same mechanism that expands your volume also tends to lower your blood potassium, and low potassium is not something to take lightly, because potassium matters for how the heart and muscles fire.

This is why fludrocortisone comes with lab monitoring built in. Your clinician typically checks potassium after starting and after dose changes, and may suggest potassium-rich foods or a supplement if it drifts low. It is a manageable, expected part of the drug, not a surprise, and it is one of the main reasons fludrocortisone is a prescribe-and-monitor medication rather than a set-and-forget one.

A few other things get watched, all following logically from a drug that expands fluid volume:

• Blood pressure. Expanding volume raises pressure, which is usually the goal, but it can overshoot. Lying and standing blood pressure are both worth having.
• Swelling and weight. A little ankle swelling or a few pounds of water can appear as volume climbs. Sudden weight gain or noticeable edema is worth flagging.
• Headache. A recognized effect, often as the dose is finding its level.
• Supine hypertension. As with other volume and pressure-raising treatments, blood pressure that runs too high lying down can occur and is checked during titration.

At the low doses used for POTS, fludrocortisone’s glucocorticoid (steroid-type) activity is minimal, so the effects people associate with steroids like prednisone are not the main concern here. Still, it is not abruptly stopped at higher doses, and your prescriber manages any changes. None of this is a reason to fear the drug; it is the reason it is dosed carefully and followed with labs.

What fludrocortisone does to your stand test

The orthostatic stand test is where fludrocortisone’s effect is easiest to see over time, and it is worth measuring both numbers, because the drug’s story lives in how they move together across weeks rather than in any single reading.

• The standing heart-rate jump often shrinks. As blood volume expands and more blood returns to the heart on standing, the reflex tachycardia has less to correct for. A lying-to-standing jump that trends smaller and steadier over several weeks is the pattern you are hoping to see.
• Standing blood pressure should hold up better. More volume means more pressure to work with when you stand, so a standing systolic that used to sag may hold flatter.

Because fludrocortisone builds slowly, patience is part of using it. Do not judge it on day two. Keep taking the test the same way, at the same time of day, with the same salt and fluid habits, so you are comparing like with like, and read the multi-week trend.

How fludrocortisone changes your HRV numbers

Fludrocortisone’s effect on heart rate variability is indirect, and worth reading carefully so you do not over-interpret it. A beta blocker raises HRV two ways at once, by slowing the heart and by shifting autonomic balance toward the parasympathetic side. Fludrocortisone does neither of those directly, because it never acts on the heart.

What it can do is change the conditions your autonomic nervous system is operating under. By expanding blood volume and reducing the standing stress that provokes a sympathetic surge, it may allow a modestly calmer autonomic tone, which can show up as a small lift in a metric like RMSSD or high-frequency power. But the effect is smaller, slower, and less predictable than a rate-lowering drug produces, and it varies a lot between people. The honest takeaway is not to read too much into a small HRV shift after starting fludrocortisone. Its real job is your volume and your stand test, not your RMSSD.

The practical response is the same one that works for any change in your regimen:

• Treat a dose or salt change as a fresh baseline. Do not compare readings from before and after as if they belong to one story; you have two now.
• Measure at a consistent time of day, with consistent salt and fluid habits, so you are not comparing a well-hydrated morning against a depleted one.
• Watch the multi-week trend on a steady regimen, plus your symptom load, rather than reacting to a single reading.

What to track on fludrocortisone

Frequently asked questions

How does fludrocortisone help POTS? It is a synthetic mineralocorticoid that acts on the kidneys, telling them to hold on to sodium so water follows and blood volume expands. In the low-volume, pooling type of POTS, a bigger volume means more blood returns to the heart on standing, standing circulation holds up, and the reflex heart-rate jump often shrinks as a result.

Does fludrocortisone lower heart rate? Not directly; it does not act on the heart. But by expanding blood volume and easing the standing shortfall that provokes tachycardia, it can shrink the lying-to-standing heart-rate jump, so the standing heart rate often improves as a downstream effect.

Why do I have to eat more salt on fludrocortisone? Because the drug retains sodium rather than creating it. On a low-salt diet there is little for it to hold, so it has almost nothing to work with. The higher salt and fluid intake supply the raw material the medication keeps in.

What are fludrocortisone’s side effects? Lower blood potassium from trading sodium for potassium in the kidney, plus fluid-related effects like ankle swelling, headache, water weight, and blood pressure that can run too high if volume expands too far. At the low POTS doses the steroid-type effects are minimal. Your clinician monitors potassium, blood pressure, and weight.

How is fludrocortisone different from midodrine for POTS? Fludrocortisone expands blood volume by making the kidneys retain salt and water. Midodrine tightens blood vessels so the blood you have pools less. One fills the tank, the other narrows the pipes, and they are sometimes combined depending on subtype and your clinician’s judgement.

The bottom line

Fludrocortisone is the POTS drug that works from a third direction. Instead of slowing the heart or tightening the vessels, it acts on the kidneys as a synthetic mineralocorticoid, making them hold on to sodium so water follows and blood volume expands. That makes it a strong fit when low blood volume is the core problem, and a poor fit when a racing, hyperadrenergic heart with normal or high pressure dominates. It only works if enough salt and fluid are coming in, it builds slowly over days rather than acting within the hour, and it carries one rule of its own: because the kidneys trade sodium for potassium, your clinician watches your potassium along with your blood pressure and weight. Track your standing heart-rate jump, your resting heart rate, and your salt and fluid habits, read any HRV change as a small, indirect effect rather than a cure, and keep every dose and monitoring decision a conversation with the clinician who prescribes it.